Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 17Trastuzumab 16Paclitaxel 15Doxorubicin 11Docetaxel 10Radiotherapy 9Carboplatin 9Capecitabine 9Bevacizumab 8Lapatinib 7Taxes 6Tamoxifen 6Gemcitabine 5Filgrastim 5Chemotherapy, Adjuvant 5sargramostim 4Sorafenib 4Radiation 4Neoadjuvant Therapy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Vinorelbine 3Thiotepa 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Irinotecan 3Immunohistochemistry 3Granulocyte Colony-Stimulating Factor 3Erlotinib Hydrochloride 3Anastrozole 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms, Male × Drug Screening Assays, Antitumor × Clear all
NCT00003253 2013-12-19

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
100 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡